Monopar Therapeutics Inc. (NASDAQ:MNPR) Short Interest Update

by · The Markets Daily

Monopar Therapeutics Inc. (NASDAQ:MNPR – Get Free Report) was the target of a large increase in short interest in the month of February. As of February 28th, there was short interest totalling 51,300 shares, an increase of 57.8% from the February 13th total of 32,500 shares. Currently, 1.3% of the company’s shares are sold short. Based on an average daily trading volume, of 66,900 shares, the short-interest ratio is presently 0.8 days.

Monopar Therapeutics Trading Up 0.9 %

Shares of MNPR traded up $0.26 on Friday, reaching $29.75. 20,431 shares of the company’s stock traded hands, compared to its average volume of 361,716. The stock’s 50 day simple moving average is $35.77 and its two-hundred day simple moving average is $21.41. Monopar Therapeutics has a 52-week low of $1.72 and a 52-week high of $54.30. The stock has a market cap of $181.53 million, a PE ratio of -15.10 and a beta of 1.18.

Analysts Set New Price Targets

MNPR has been the topic of a number of analyst reports. HC Wainwright lifted their target price on shares of Monopar Therapeutics from $22.00 to $40.00 and gave the stock a “buy” rating in a research note on Wednesday, January 22nd. Piper Sandler assumed coverage on Monopar Therapeutics in a research report on Friday, January 10th. They issued an “overweight” rating and a $72.00 target price for the company.

Read Our Latest Report on MNPR

Institutional Investors Weigh In On Monopar Therapeutics

Several institutional investors have recently made changes to their positions in the stock. Janus Henderson Group PLC bought a new stake in shares of Monopar Therapeutics during the fourth quarter valued at about $23,435,000. Adage Capital Partners GP L.L.C. bought a new stake in Monopar Therapeutics during the 4th quarter worth approximately $13,182,000. RA Capital Management L.P. purchased a new stake in Monopar Therapeutics in the 4th quarter worth approximately $11,247,000. Point72 Asset Management L.P. bought a new position in Monopar Therapeutics in the 4th quarter valued at $3,694,000. Finally, ADAR1 Capital Management LLC bought a new position in shares of Monopar Therapeutics in the fourth quarter worth $2,861,000. Hedge funds and other institutional investors own 1.83% of the company’s stock.

About Monopar Therapeutics

(Get Free Report)

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.

Read More